SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

BLS BLS Pharmaceuticals Limited

Healthcare · Biotechnology · website
$1.02
52wk 0.33 – 1.29
Overall
85.3
Value
48.0
Growth
100.0
Health
98.9
Quality
97.7
Momentum
84.9
Dividend
—
Price
About BLS Pharmaceuticals Limited

BLS Pharmaceuticals Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czech Republic, and Japan. The company offers medical cannabis, MDMA, psilocybin, prescription medicines, probiotics, NADs, and consumer health products under the Dr Watson and PCC brands. It also provides pharmaceutical manufacturing, wholesale, distribution, import, export, and contract drug manufacturing services for investigational and psychotropic medicines. The company caters to licensed clinics, pharmacies, wholesale distributors, cultivators, active pharmaceutical ingredient manufacturers, and pharmaceutical brand sponsors. The company was formerly known as Bioxyne Limited and changed its name to BLS Pharmaceuticals Limited in June 2026. BLS Pharmaceuticals Limited was incorporated in 1998 and is headquartered in Sydney, Australia.

Price analytics

Returns

1 day 0.0%
1 week -1.0%
1 month -8.1%
3 months 9.7%
6 months 67.2%
1 year 161.5%
3 years 750.0%

Risk

Volatility (1y ann.) 77.9%
Beta vs ASX 200 1.21
Sharpe (1y) 1.56
VaR 95% (1-day) -7.0%
Max drawdown (1y) -26.0%
Off 1-year high -20.9%

Technicals

RSI(14) 36
vs 50DMA 1.4%
vs 200DMA 39.0%
Trend Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 48.0
Trailing P/E
80
Forward P/E
—
PEG ratio
13
EV / EBITDA
54
Price / Book
6
Price / Sales
74
Growth 100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
100
EPS growth (1y)
100
EPS CAGR (3y)
—
Financial Health 98.9
Net debt / EBITDA
100
Interest coverage (EBIT/interest)
100
Current ratio
100
Debt / Equity
96
Quality (Profitability & Cash Flow) 97.7
Return on equity
100
Return on assets
100
Operating margin
90
Net margin
100
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 84.9
6-month return vs ASX 200
100
Price vs 200-day average
100
Price vs 50-day average
57
Position in 52-week range
72

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$235.28M
P/E (trailing)
14.57
P/E (forward)
—
EPS (trailing)
0.07
Dividend yield
—
Payout ratio
0.0%
Beta
0.65
EV / EBITDA
11.43
Price / Book
7.56
ROE
71.3%
Operating margin
22.6%
Net margin
20.8%
Total cash
$13.29M
Total debt
$8.43M
Current ratio
2.90
Debt / Equity
0.27
Free cash flow
$-1.86M
Avg volume
335,078
Latest annual results (FY ending 30 Jun 2026)
  • Revenue$74.16M
  • Gross profit$41.56M
  • Operating income$15.80M
  • Net income$15.40M
  • Diluted EPS0.07
  • Free cash flow$1.95M
  • Net debt-$4.86M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4